Bovine Colostrum Supplementation Research Articles

Bovine colostrum supplementation enhances sensitivity of the in vivo immune response to a novel antigen following prolonged exercise

Bovine colostrum supplementation enhances sensitivity of the in vivo immune response to a novel antigen following prolonged exercise

No effect of acute or chronic bovine colostrum supplementation on circulating insulin-like growth factor-I

No effect of acute or chronic bovine colostrum supplementation on circulating insulin-like growth factor-I

The effects of bovine colostrum supplementation on in vivo immunity following prolonged exercise: a randomised controlled trial

BackgroundBovine colostrum (COL) has been advocated as a nutritional countermeasure to exercise-induced immune dysfunction, but there is a lack of research with clinically relevant in vivo measures.AimTo investigate the effects of COL supplementation on in vivo immunity following prolonged exercise using experimental contact hypersensitivity (CHS) with the novel antigen diphenylcyclopropenone (DPCP).MethodsIn a double-blind design, 31 men were randomly assigned to COL (20 g/day) or placebo (PLA) for 58 days. Participants ran for 2 h at 60% maximal aerobic capacity on day 28 and received a primary DPCP exposure (sensitisation) 20 min after. On day 56, participants received a low-dose-series DPCP challenge to elicit recall of in vivo immune-specific memory (quantified by skinfold thickness 24 and 48 h later). Analysis of the dose–response curves allowed determination of the minimum dose required to elicit a positive response (i.e., sensitivity).ResultsThere was no difference in summed skinfold thickness responses between COL and PLA at 24 h (p = 0.124) and 48 h (p = 0.405). However, sensitivity of in vivo immune responsiveness was greater with COL at 24 h (p < 0.001) and 48 h (p = 0.023) with doses ~ twofold greater required to elicit a positive response in PLA.ConclusionsCOL blunts the prolonged exercise-induced decrease in clinically relevant in vivo immune responsiveness to a novel antigen, which may be a mechanism for reduced illness reports observed in the previous studies. These findings also suggest that CHS sensitivity is highly relevant to host defence.

OR082 Bovine colostrum supplementation in respiratory allergies according to sensitization: subgroup analysis of randomized controlled trial

OR082 Bovine colostrum supplementation in respiratory allergies according to sensitization: subgroup analysis of randomized controlled trial

Bovine colostrum supplementation does not affect plasma I-FABP concentrations following exercise in a hot and humid environment.

To quantify the impact of a 14-day bovine colostrum (BC) supplementation on intestinal cell damage following exercise in a hot and humid environment. Ten male participants (20 ± 2years, VO2max 55.80 ± 3.79mLkg-1min-1, 11.81 ± 2.71% body fat) ran for 46 ± 7.75min at 95% of ventiliatory threshold in 40°C and 50% RH following a 14-day double-blinded supplementation with either BC or placebo (Plac). Core temperature, skin temperature, heart rate, and rating of perceived exertion were recorded every 5min during exercise. Blood was taken pre, post, 1h, and 4h post exercise. Intestinal cell damage was assessed via intestinal fatty acid binding protein (I-FABP). I-FABP concentrations were similar between conditions at all time points [pre 989.39 ± 490.88pgml-1 (BC) 851.35 ± 450.71 pgml-1 (Plac) post 1505.10 ± 788.63 pgml-1 (BC) 1267.12 ± 521.51 pgml-1 (Plac) 1-h, 1087.77 ± 397.06pgml-1 (BC) 997.25 ± 524.74 pgml-1 (Plac) 4-h, 511.35 ± 243.10 pgml-1 (BC) 501.46 ± 222.54 pgml-1 (Plac)]. I-FABP was elevated pre to post exercise for both BC (162 ± 50%) and Plac (162 ± 56%) (p < 0.05). BC had no effect on mean body temperature [beginning 36.11 ± 0.30°C, ending: 39.52 ± 0.28°C (BC); beginning:35.96 ± 0.43°C, ending:39.42 ± 0.38°C (Plac)]. While BC supplementation may protect against enterocyte damage during exercise in thermonuetral environments, our data suggest that BC supplementation may not be an effective technique for preventing enterocyte damage during exercise when core temperature exceeds 39°C.

Effect of human milk formula with bovine colostrum supplementation on bone mineral density in infant cynomolgus macaques.

Insulin-like growth factor 1 (IGF1) is a regulator of human growth during infancy and childhood, known to promote bone and muscle growth as well as lipid accumulation. This study aimed to investigate the effects of formula milk with or without IGF1 supplementation (in the form of pure IGF1 or bovine colostrum) on growth and body composition in infant cynomolgus macaques during the first 6 months of life. Three groups of infants were nursery-reared and received formula milk with or without IGF1 or bovine colostrum supplementation for 4 months, and a fourth group consisting of breast-fed infants was included for comparison (n=6 for each group). Ranked-based analysis of covariance was used to detect differences between adjusted means for sex. No differences in weight, height, fat mass, and fat-free mass could be detected between groups. However, bone mineral density (BMD) was significantly different between groups at the end of formula feeding. Infants that received bovine colostrum supplementation displayed higher mean BMD than infants of all other groups, with no differences between the latter three groups. In conclusion, our results suggest that supplementation with bovine colostrum can enhance BMD in formula-fed infants, an effect that apparently does not depend on IGF1. Bovine colostrum supplementation could be beneficial for long-term bone health in infants with suboptimal bone growth.

Intestinal fatty acid-binding protein and gut permeability responses to exercise

PurposeIntestinal cell damage due to physiological stressors (e.g. heat, oxidative, hypoperfusion/ischaemic) may contribute to increased intestinal permeability. The aim of this study was to assess changes in plasma intestinal fatty acid-binding protein (I-FABP) in response to exercise (with bovine colostrum supplementation, Col, positive control) and compare this to intestinal barrier integrity/permeability (5 h urinary lactulose/rhamnose ratio, L/R).MethodsIn a double-blind, placebo-controlled, crossover design, 18 males completed two experimental arms (14 days of 20 g/day supplementation with Col or placebo, Plac). For each arm participants performed two baseline (resting) intestinal permeability assessments (L/R) pre-supplementation and one post-exercise following supplementation. Blood samples were collected pre- and post-exercise to determine I-FABP concentration.ResultsTwo-way repeated measures ANOVA revealed an arm × time interaction for L/R and I-FABP (P < 0.001). Post hoc analyses showed urinary L/R increased post-exercise in Plac (273% of pre, P < 0.001) and Col (148% of pre, P < 0.001) with post-exercise values significantly lower with Col (P < 0.001). Plasma I-FABP increased post-exercise in Plac (191% of pre-exercise, P = 0.002) but not in the Col arm (107%, P = 0.862) with post-exercise values significantly lower with Col (P = 0.013). Correlations between the increase in I-FABP and L/R were evident for visit one (P = 0.044) but not visit two (P = 0.200) although overall plots/patterns do appear similar for each.ConclusionThese findings suggest that exercise-induced intestinal cellular damage/injury is partly implicated in changes in permeability but other factors must also contribute.

A low-dose, 6-week bovine colostrum supplementation maintains performance and attenuates inflammatory indices following a Loughborough Intermittent Shuttle Test in soccer players

PurposeThe aim of the study was to investigate the effect of a 6-week, low-dose bovine colostrum (BC) supplementation on exercise-induced muscle damage (EIMD) and performance decline in soccer players following the Loughborough Intermittent Shuttle Test (LIST) during a competitive season period.MethodsIn a double-blind, randomized, placebo-controlled design, two groups of soccer players were allocated to a 3.2 g/day of whey protein (WP, N = 8) or BC (N = 10) and performed a pre- and a post-supplementation LIST. Maximum isometric voluntary contraction, squat jump (SQJ), countermovement jump, muscle soreness, blood cell counts, creatine kinase (CK), C-reactive protein (CRP) and interleukin-6 (IL-6) were monitored for 2, 24, 48, 72 h post-LIST.ResultsLIST induced transient increases in leukocytes, granulocytes, CK, muscle soreness, CRP, IL-6 and declines in lymphocytes and performance indices. Supplementation resulted in a faster recovery of SQJ, CK and CRP compared to pre-supplementation kinetics (trial × time: p = 0.001, 0.056, 0.014, respectively) and lower incremental area under the curve (iAUC) for IL-6, only in the BC group [pre-: 31.1 (6.78–46.9), post-: 14.0 (−0.16 to 23.5) pg h/ml, p = 0.034]. Direct comparison of the two groups after supplementation demonstrated higher iAUC of SQJ [WP: −195.2 (−229.0 to (−52.5)), BC: −15.8 (−93.2 to 16.8) cm h, p = 0.034], a trend for lower iAUC of CK in the BC group [WP: 18,785 (4651–41,357), BC: 8842 (4807–14,802) U h/L, p = 0.081] and a significant intervention × time interaction for CRP (p = 0.038) in favor of BC.ConclusionsPost-exercise EIMD may be reduced and performance better maintained by a low dose of BC administration following LIST in soccer players.

A Stepwise, Pilot Study of Bovine Colostrum to Supplement the First Enteral Feeding in Preterm Infants (Precolos): Study Protocol and Initial Results.

The optimal feeding for preterm infants during the first weeks is still debated, especially when mother's own milk is lacking or limited. Intact bovine colostrum (BC) contains high amounts of protein, growth factors, and immuno-regulatory components that may benefit protein intake and gut maturation. We designed a pilot study to investigate the feasibility and tolerability of BC as the first nutrition for preterm infants. The study was designed into three phases (A, B, and C) and recruited infants with birth weights of 1,000-1,800 g (China) or gestational ages (GAs) of 27 + 0 to 32 + 6 weeks (Denmark). In phase A, three infants were recruited consecutively to receive BC as a supplement to standard feeding. In phase B, seven infants were recruited in parallel. In phase C (not yet complete), 40 infants will be randomized to BC or standard feeding. Feeding intolerance, growth, time to full enteral feeding, serious infections/NEC, plasma amino acid profile, blood biochemistry, and intestinal functions are assessed. This paper presents the study protocol and results from phases A and B. Seven Danish and five Chinese infants received 22 ± 11 and 22 ± 6 ml·kg-1·day-1 BC for a mean of 7 ± 3 and 7 ± 1 days which provided 1.81 ± 0.89 and 1.83 ± 0.52 g·kg-1·day-1 protein, respectively. Growth rates until 37 weeks or discharge were in the normal range (11.8 ± 0.9 and 12.9 ± 2.7 g·kg-1·day-1 in Denmark and China, respectively). No clinical adverse effects were observed. Five infants showed a transient hypertyrosinemia on day 7 of life. The three-phased study design was used to proceed with caution as this is the first trial to investigate intact BC as the first feed for preterm infants. BC supplementation appeared well tolerated and resulted in high enteral protein intake. Based on the safety evaluation of phases A and B, the randomized phase C has been initiated. When complete, the Precolos trial will document whether it is feasible to use BC as a novel, bioactive milk diet for preterm infants. Our trial paves the way for a larger randomized controlled trial on using BC as the first feed for preterm infants with insufficient access to mother's own milk.

Doxorubicin-Induced Gut Toxicity in Piglets Fed Bovine Milk and Colostrum.

Chemotherapy-induced intestinal toxicity is a common adverse effect of cancer treatment. We hypothesized that a milk diet containing bovine colostrum (BC) would reduce intestinal toxicity in doxorubicin-treated piglets. "Study 1" investigated intestinal parameters 9 days after a single dose of doxorubicin (1 × 75 mg/m) in piglets fed bovine milk enriched with whey protein (BM). In "study 2," responses to doxorubicin treatment were investigated in piglets receiving either 7 BC feedings per day (Only-BC, n = 13), 4 BC feedings (High-BC, n = 13), 2 BC feedings (Low-BC, n = 14), or no BC (only BM, n = 13). Doxorubicin treatment induced clinical signs of intestinal toxicity with diarrhea and weight loss, relative to controls (P < 0.05). White blood cells, hexose absorptive function, plasma citrulline, weights of intestine, colon, and spleen were reduced, whereas gut permeability and plasma C-reactive protein levels were increased (all P < 0.05). Limited or no effects were observed for digestive enzymes, proinflammatory cytokines, or tight-junction proteins in the intestine. Increasing BC supplementation to doxorubicin-treated piglets (study 2) had no consistent effects on plasma C-reactive protein and citrulline levels, intestinal morphology, digestive enzymes, permeability, or proinflammatory cytokines. Only-BC pigs, however, had lower diarrhea severity toward the end of the experiment (P < 0.05 vs BM) and across the BC groups, intestinal toxicity was reduced (P < 0.01). Doxorubicin-treated piglets are relevant for studying chemotherapy-induced gut toxicity. Colostrum supplementation had limited effects on doxorubicin-induced toxicity in milk-fed piglets suggesting that colostrum and a bovine milk diet enriched with whey protein provided similar protection of the developing intestine from chemotherapy-induced toxicity.

Bovine colostrum supplementation and upper respiratory symptoms during exercise training: a systematic review and meta-analysis of randomised controlled trials.

BackgroundBovine colostrum is proposed as a nutritional countermeasure to the risk of upper respiratory symptoms (URS) during exercise training. The aim of this systematic review and meta-analysis was to estimate the size of the effect of bovine colostrum supplementation on URS.MethodsDatabases (CDSR, CENTRAL, Cinahl, ClinicalTrials.gov, Current Controlled Trials, DARE, EMBASE, Medline, PROSPERO and Web of Science) of published, unpublished and ongoing studies were searched for randomised controlled trials of healthy adults (≥18 years), evaluating the effect of oral bovine colostrum supplementation compared to a concurrent control group on URS.ResultsFive trials (152 participants) met the inclusion criteria, all of which involved individuals involved in regular exercise training. Over an 8–12 week follow-up period, bovine colostrum supplementation when compared to placebo significantly reduced the incidence rate of URS days (rate ratio 0.56, 95 % confidence intervals 0.43 to 0.72, P value < 0.001) and URS episodes (0.62, 0.40 to 0.99, P value = 0.04) by 44 and 38 % respectively. There were limited data and considerable variation in results of included studies for duration of URS episodes hence a meta-analysis of this outcome was deemed inappropriate. The risk of bias assessment in this review was hindered by poor reporting practices of included studies. Due to incomplete reporting of study methods, four of the five studies were judged to have a moderate or high risk of overall bias. Our findings must be interpreted in relation to quantity and quality of the available evidence.ConclusionsThe present systematic review and meta-analysis provides evidence that bovine colostrum supplementation may be effective in preventing the incidence of URS days and episodes in adults engaged in exercise training. The fact that the majority of included studies did not report significant effects on URS outcomes mitigates concerns about publication bias. The point estimates of the random-effects meta-analyses are greater than the smallest clinically important difference, but the low precision of the individual study estimates means the evidence presented in this review needs to be followed up with an appropriately designed and adequately powered, randomised control trial.Trial registrationProtocol was registered (CRD42015014925) on the International Prospective Register of Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO/).Electronic supplementary materialThe online version of this article (doi:10.1186/s13102-016-0047-8) contains supplementary material, which is available to authorized users.

Enhanced Bovine Colostrum Supplementation Shortens the Duration of Respiratory Disease in Thoroughbred Yearlings

Abstract Bovine colostrum (BC) is used in humans as a nutritional supplement for immune support and has been shown to reduce Respiratory disease (RD). Other nutritional supplements, minerals and vitamins including mannan oligosaccharides (MOS), zinc and vitamins A, C and E have also been used for immune support. The aim of this prospective blinded randomized clinical trial was to evaluate the effects of a BC, MOS, zinc and vitamin based enhanced bovine colostrum supplement (BCS) on incidence and duration of RD occurring in yearling horses. 109 yearlings on two Thoroughbred farms in Central Kentucky were randomly assigned to treatment or placebo groups. Yearlings were supplemented once daily for 17 to 25 weeks with 100 g of a high quality commercial BCS (containing 50 g BC) or a full fat soy flour placebo, which were applied as a “top-dress” to feed. Yearlings were observed daily and evaluated weekly for signs of RD. All yearlings completed the study. The proportion of the study period during which each yearling exhibited illness was considerably shorter for BCS yearlings (least squares mean = 23% of the study period) than placebo yearlings (least squares mean = 34% of the study period, P = .002). The average duration of illness was shorter for BCS yearlings (1.96 weeks) than placebo yearlings (4.39 weeks, P

Potential benefits of colostrum in gastrointestinal diseases.

This paper reviews the composition of colostrum and the potential preventive and therapeutic use of this "first milk" for treating various gastrointestinal disorders in humans. Colostrum is a complex biological liquid that is richer in antimicrobial peptides, immune-regulating compounds and growth factors than the subsequent mature milk. The main functions of colostrum are to provide essential nutritional components, strengthen the natural defense system, modulate immune response, balance intestinal microbiota and enhance the growth and repair of several tissues. Several studies and clinical trials carried out both in vitro and in vivo on humans and animals suggest the clinical benefits of bovine colostrum (BC) supplementation in gastro-intestinal diseases. Despite the encouraging results, further well-designed studies are required in order to confirm these effects, the dose and duration of treatment. Colostrum is safe since there are no contraindications regarding high dose levels and few side effects of clinical relevance have been reported. In conclusion, in the near future, colostrum-based supplements may play a complementary role to synthetic drugs in the prevention and treatment of various gastrointestinal disorders.

Effects of bovine colostrum on performance, survival, and immunoglobulin status of suckling piglets during the first days of life

Supplementation of bovine colostrum (BC) has shown to improve growth performance, intestinal development, and immune response in early-weaned pigs. Little is known about whether BC may have similar effects in neonatal piglets. In the present study, the effect of BC supplementation on mortality, growth performance, and blood parameters (plasma proteins and white blood count) of suckling piglets in the first 10&amp;nbsp;days of life was investigated under practical conditions with special emphasis on low birth weight piglets. In total, 258 newborn piglets from 30 multiparous sows in a commercial breeding unit were randomly assigned to two different treatment groups. Piglets received either 1 ml of BC orally on days 1&amp;ndash;3 of life (group BC, n = 128) or 1 ml of saline (0.9%) (control (CON) group; n = 130). Body weight was measured on days 1, 4, and 10 of life. Blood was collected on days 1 and 4 from 60 piglets per group. No differences in mortality, body weight, and average daily weight gain were observed between treatment groups in days 1&amp;ndash;10. However, compared to CON, particularly in low birth weight piglets the administration of BC supported (P &amp;lt; 0.01) their survival. Group BC exhibited lower plasma total protein (P = 0.03) and beta-globulin (P = 0.02) concentrations compared to group CON. In conclusion, BC improved low and normal birth weight piglets&amp;rsquo; survival during their first 10 days of life. Further research is needed to clarify whether the survival rate is related to earlier gut closure indicated by lower plasma protein levels, which might be beneficial due to a lower uptake of potential antigenic substances.

Influence of 4 weeks of bovine colostrum supplementation on neutrophil and mucosal immune responses to prolonged cycling.

Bovine colostrum (COL) has been advocated as a nutritional countermeasure to exercise-induced immune dysfunction. The aims of this study were to identify the effects of 4 weeks of COL supplementation on neutrophil responses and mucosal immunity following prolonged exercise. In a randomized double-blind, parallel group design, participants [age 28 ± 8 years; body mass 79 ± 7 kg; height 182 ± 6 cm; maximal oxygen uptake (V̇O2max) 55 ± 9 mL/kg/min] were assigned to 20 g per day of COL (n = 10) or an isoenergetic/isomacronutrient placebo (PLA; n = 10) for 4 weeks. Venous blood and unstimulated saliva samples were obtained before and after 2.5 h of cycling at 15% Δ (∼55-60% V̇O2max). A significantly greater formyl-methionyl-leucyl phenylalanine-stimulated oxidative burst was observed in the COL group compared with PLA group (P < 0.05) and a trend toward a time × group interaction (P = 0.06). However, there was no effect of COL on leukocyte trafficking, phorbol-12-myristate-13-acetate-stimulated oxidative burst, bacterial-stimulated neutrophil degranulation, salivary secretory IgA, lactoferrin or lysozyme (P > 0.05). These findings provide further evidence of the beneficial effects of COL on receptor-mediated stimulation of neutrophil oxidative burst in a model of exercise-induced immune dysfunction.

Bovine colostrum supplementation: Potential benefits in human and animal health

Bovine colostrum supplementation: Potential benefits in human and animal health

Bovine colostrum, training status, and gastrointestinal permeability during exercise in the heat: a placebo-controlled double-blind study.

Heat stress can increase gastrointestinal permeability, allowing ingress of gram-negative bacterial fragments and thus potentially inflammation and ultimately endotoxemia. Permeability may rise with intense exercise, yet some data indicate that endotoxemia may be mitigated with bovine colostrum supplementation. Using a double-blind, randomised, placebo-controlled crossover study, we tested whether bovine colostrum (COL; 1.7 g·kg(-1)·day(-1) for 7 days) would attenuate physiological strain and aid exercise capacity in the heat, especially in untrained individuals. Seven trained men (T; peak oxygen uptake 64 ± 4 mL·kg(-1)·min(-1)) and 8 untrained men (UT, peak oxygen uptake 46 ± 4 mL·kg(-1)·min(-1)) exercised for 90 min in 30 °C (50 % relative humidity) after COL or placebo (corn flour). Exercise consisted of 15-min cycling at 50 % heart rate reserve (HRR) before and after 60 min of running (30 min at 80 % HRR then 30-min distance trial). Heart rate, blood pressure (Finometer), esophageal, and skin temperatures were recorded continuously. Gastrointestinal permeability was assessed from urine (double-sugar model, using high-performance liquid chromatography) and blood (intestinal fatty acid-binding protein, I-FABP). The T group ran ∼2.4 km (35%) further than the UT group in the distance trial, and I-FABP increased more in the T group than in the UT group, but physiological and performance outcomes were unaffected by colostrum supplementation, irrespective of fitness. Circulating pro- and anti-inflammatory cytokine concentrations were higher following exercise, but were not modulated by fitness or COL. Despite substantial thermal and cardiovascular strain incurred in environmental conditions in which exertional endotoxemia may occur, bovine colostrum supplementation had no observable benefit on the physiology or performance of either highly trained endurance athletes or untrained individuals.

Bovine Colostrum Supplementation Does Not Influence Serum Insulin-like Growth Factor-1 in Horses in Race Training

Bovine colostrum (BC) is a commonly used food supplement in humans for both immune support and athletic performance enhancement; the latter effect has been attributed in some studies to an increase in the anabolic cytokine Insulin-like Growth Factor-1 (IGF-1). The aim of the present study was to determine the effect of BC supplementation on serum IGF-1 in racing horses. Five serum IGF-1 samples were collected from 12 horses in race training every 2 weeks over an 8-week period from November to January. Six horses received BC supplementation for 4 weeks, starting at the 2-week point. The expected seasonal IGF-1 decrease over the November to January study period was observed, but there was no effect of BC supplementation on serum IGF-1 concentrations as compared with the untreated controls.

Clinical applications of bovine colostrum therapy: a systematic review

Bovine colostrum, the first milk that cows produce after parturition, contains high levels of growth factors and immunomodulatory components. Some healthy and diseased individuals may gain health benefits by consuming bovine colostrum as a food supplement. This review provides a systematic, critical evaluation of the current state of knowledge in this area. Fifty-one eligible studies were identified from the following databases: Medline, Embase, Global Health, the Cochrane Library, and the Cumulative Index to Nursing and Allied Health Literature. Studies were heterogeneous with regard to populations, outcomes, and methodological quality, as judged by the Jadad assessment tool. Many studies used surrogate markers to study the effects of bovine colostrum. Studies suggesting clinical benefits of colostrum supplementation were generally of poor methodological quality, and results could not be confirmed by other investigators. Bovine colostrum may provide gastrointestinal and immunological benefits, but further studies are required before recommendations can be made for clinical application. Animal models may help researchers to better understand the mechanisms of bovine colostrum supplementation, the dosage regimens required to obtain clinical benefits, and the optimal methods for testing these effects in humans.

Bovine colostrum supplementation optimises earnings, performance and recovery in racing Thoroughbreds

Bovine colostrum (BC) is the first milk produced by cows after calving and contains numerous beneficial substances for the immunity and development of the newborn calf. Because of the growth and immune factors in BC, it has become an attractive supplement for use by athletes to support immunity and health during athletic performance. In order to evaluate the effects of oral BC supplementation on equine athletes, this study evaluated the earnings, performance, recovery and incidence of upper respiratory infections (URTI) in racing horses. The study design was a randomized cross-over racing performance study. 21 horses in race training were randomly assigned to train and compete with or without BC supplementation. After each horse competed in three races, it was crossed over to the other group, allowed a three week washout period, and then competed in three additional races. Horses in public training stables of 3 participating trainers were used. Race performance as determined by earnings, Bloodstock Research Information System (BRIS) speed figures, recovery as determined by number of days between races and incidence of upper respiratory tract disease was recorded. 11 horses completed the study. There was no effect of the order of BC supplementation on the measured variables. Horses on BC supplementation earned $ 2,088 more purse money per race, than when unsupplemented (P=0.016), and ran an average of 5 BRIS speed points higher (P=0.03). Horses returned to racing on average 7.5 days faster (16.9 days vs 24.4 days, P=0.048). There were no URTI among the horses on BC supplementation and two infections while not on BC supplementation (z-test, P=0.11). Statistical analysis showed that horses recovered more quickly, earned three times more money and raced better as judged by BRIS scores while competing with BC supplementation. BC supplemented horses also experienced fewer URTI, although this effect was not significant.